Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Treace Medical Concepts ( (TMCI) ) just unveiled an announcement.
On December 17, 2025, Treace Medical Concepts entered into new five-year senior secured loan agreements with credit funds managed by SLR Capital Partners, establishing up to $175 million in total debt capacity through a $125 million term loan facility and a revolving credit facility that can reach $50 million, replacing prior credit lines with MidCap Financial Trust. The company drew $60 million at closing, used the proceeds to repay its $50 million term loan and $4 million outstanding under its former revolver while incurring $2.3 million in associated prepayment and exit fees, and emerged with approximately $165 million in total liquidity, although the new covenants restrict dividend payments and are secured by substantially all assets, including intellectual property. The financing, which carries SOFR-based interest rates with an initial 48-month interest-only period and potential extension, is intended to provide Treace with non-dilutive capital, enhance balance sheet strength and financial flexibility, and support its efforts to expand its market presence in bunion surgery. Separately, on December 16, 2025, the board appointed veteran healthcare executive and existing director John K. Bakewell as lead independent director, reinforcing governance with an experienced financial and medical device industry leader.
The most recent analyst rating on (TMCI) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Treace Medical Concepts stock, see the TMCI Stock Forecast page.
Spark’s Take on TMCI Stock
According to Spark, TipRanks’ AI Analyst, TMCI is a Neutral.
Treace Medical Concepts faces significant challenges with profitability and cash flow, reflected in a low financial performance score. Technical analysis indicates strong bearish momentum, and valuation metrics are poor due to negative earnings. While the earnings call showed some positive strategic shifts, the overall outlook remains cautious.
To see Spark’s full report on TMCI stock, click here.
More about Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has pioneered and patented the Lapiplasty 3D Bunion Correction System, a suite of instruments, implants and surgical methods designed to correct bunions in all three planes and stabilize the unstable midfoot joint, and also markets the Adductoplasty Midfoot Correction System, minimally invasive Nanoplasty and Percuplasty bunion correction systems, the SpeedMTP MTP Fusion System, and SpeedPlate rapid compression implants, supported by its IntelliGuide digital pre-operative planning and patient-specific cut guide technology.
Average Trading Volume: 657,134
Technical Sentiment Signal: Sell
Current Market Cap: $172M
Find detailed analytics on TMCI stock on TipRanks’ Stock Analysis page.